Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18 clinical trials
A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain

The purpose of this study is to assess the percent change in body weight when switching to darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC

  • 0 views
  • 21 May, 2021
  • 34 locations
A Study in Healthy Participants to Assess the Effect of Darunavir Emtricitabine and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents

the presence of cobicistat (COBI) when administered as an fixed dose combination (FDC) (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide [D/C/F/TAF]) compared to the co-administration as the

  • 0 views
  • 12 Jun, 2021
  • 1 location
Pharmacokinetic Safety and Efficacy of B/F/TAF in HIV-1 Infected Virologically Suppressed Pregnant Women in Their Second and Third Trimesters

The primary objective of this study is to evaluate the steady state pharmacokinetics of bictegravir (BIC) and confirm the dose of BIC/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg

  • 60 views
  • 12 Jun, 2021
  • 19 locations
Study Evaluating Pharmacokinetics (PK) Safety and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Virologically Suppressed Pediatric Participants

to < 12 years of age) To evaluate the steady-state PK of tenofovir alafenamide (TAF) and confirm the dose of emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected pediatric

emtricitabine
antiretroviral
tuberculosis
atazanavir
cobicistat
  • 236 views
  • 18 Jun, 2021
  • 41 locations
Randomized Double-blind Efficacy and Safety Study of Doravirine/Islatravir (DOR/ISL) in Treatment-na ve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

treatment-nave participants with human immunodeficiency virus type-1 (HIV-1) infection. The primary hypothesis is that DOR/ISL is non-inferior to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF

  • 4 views
  • 13 Jun, 2021
  • 67 locations
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

compare oral ISL taken once a month with standard-of-care medication for prevention of HIV-1 infection, emtricitabine/tenofovir disoproxil (FTC/TDF), taken once per day. The primary hypothesis is that

  • 0 views
  • 17 Jun, 2021
  • 9 locations
A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

] or emtricitabine/tenofovir alafenamide [FTC/TAF]), in approximately 240 treatment-nave HIV-1 infected adults. In the experimental arms, GSK3640254 will be administered in 3 blinded doses until the

  • 0 views
  • 13 Apr, 2021
  • 44 locations
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia

, among them: Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, Emtricitabine/ Tenofovir acting over bacterial co-infection Azithromycin (Azithro), or modifying the

respiratory distress
covid-19
lopinavir/ritonavir
SARS
diabetes
  • 62 views
  • 04 Jun, 2021
  • 7 locations
Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant

This is an open-label study, where participants will be switched from their current HIV medication to the study drug, Biktarvy. Open-label means both the investigator and the participant will know what drug will be given. Participants will be followed for 48 weeks in order to monitor the efficacy, safety and …

bictegravir/emtricitabine/tenofovir
emtricitabine
biktarvy
HIV Vaccine
tenofovir
  • 0 views
  • 27 Jan, 2021
Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis

The purpose of this study is to evaluate Pre-Exposure Prophylaxis (PrEP) levels in transgender-identifying or gender non-binary individuals taking versus not taking gender affirming hormone therapy. Subjects who have previously taken F/TDF as PrEP will continue with a fixed dose combination of daily oral F/TAF substituting for F/TDF. Subjects will …

tenofovir
emtricitabine
HIV Vaccine
pre-exposure prophylaxis (prep)
  • 0 views
  • 19 Jun, 2021
  • 1 location